Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

Orabloc

&times

Overview

What is Orabloc?

Orabloc® injection is a sterile, aqueous solution that contains articaine HCl 4% (40mg/mL) and epinephrine bitartrate in an epinephrine 1:200,000 or epinephrine 1:100,000 strength. Articaine HCl is an amino amide local anesthetic, chemically designated as 4-methyl-3-[2-(propylamino)-propionamido]-2-thiophene-carboxylic acid, methyl ester hydrochloride and is a racemic mixture. Articaine HCl has a molecular weight of 320.84 and the following structural formula:

Articaine HCl has a partition coefficient in n-octanol/Soerensen buffer (pH 7.35) of 17 and a pKa of 7.8.

Epinephrine bitartrate, (-)-1-(3,4-dihydroxyphenyl)-2-methylamino-ethanol (+) tartrate (1:1) salt, is a vasoconstrictor that is added to articaine HCl in a concentration of 1:200,000 or 1:100,000 (expressed as free base). It has a molecular weight of 333.3 and the following structural formula:

Orabloc® contains articaine HCl (40 mg/mL), epinephrine (1:200,000 or 1:100,000) (as epinephrine bitartrate) sodium chloride (1.0 mg/mL), sodium metabisulfite (0.5 mg/mL), and water for injection. The product is formulated with a 10% overage of epinephrine. The pH is adjusted to 3.6 with hydrochloric acid.



What does Orabloc look like?



What are the available doses of Orabloc?

Injection (clear colorless solution), containing:

What should I talk to my health care provider before I take Orabloc?

How should I use Orabloc?

Orabloc® is an amide local anesthetic containing a vasoconstrictor indicated for local, infiltrative, or conductive anesthesia in both simple and complex dental procedures.

Table 1 (below) summarizes the recommended volumes and concentrations of Orabloc® for various types of anesthetic procedures. The dosages suggested in this table are for normal healthy adults, administered by submucosal infiltration or nerve block.

The recommended doses serve only as a guide to the amount of anesthetic required for most routine procedures. The actual volumes to be used depend on a number of factors such as type and extent of surgical procedure, depth of anesthesia, degree of muscular relaxation, and condition of the patient. In all cases, the smallest dose that will produce the desired result should be given.

The onset of anesthesia and the duration of anesthesia are proportional to the volume and concentration (i.e., total dose) of local anesthetic used. Caution should be exercised when employing large volumes because the incidence of side effects may be dose-related.

For most routine dental procedures, Orabloc® containing epinephrine 1:200,000 is preferred. However, when more pronounced hemostasis or improved visualization of the surgical field are required, Orabloc® containing epinephrine 1:100,000 may be used.


What interacts with Orabloc?

Sorry No Records found


What are the warnings of Orabloc?

Sorry No Records found


What are the precautions of Orabloc?

Sorry No Records found


What are the side effects of Orabloc?

Sorry No records found


What should I look out for while using Orabloc?

Orabloc® is contraindicated in patients who are hypersensitive to products containing sulfites. Products containing sulfites may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. Sulfite sensitivity is seen more frequently in asthmatic than in non-asthmatic people


What might happen if I take too much Orabloc?

Acute emergencies from local anesthetics are generally related to high plasma levels encountered during therapeutic use of local anesthetics or to unintended subarachnoid injection of local anesthetic solution .

The first consideration is prevention, best accomplished by careful and constant monitoring of cardiovascular and respiratory vital signs and the patient's state of consciousness after each local anesthetic injection. At the first sign of change, oxygen should be administered.

The first step in the management of convulsions, as well as hypo-ventilation, consists of immediate attention to the maintenance of a patient airway and assisted or controlled ventilation as needed. The adequacy of the circulation should be assessed. Should convulsions persist despite adequate respiratory support, treatment with appropriate anticonvulsant therapy is indicated. The practitioner should be familiar with the use of anticonvulsant drugs, prior to the use of local anesthetics. Supportive treatment of circulatory depression may require administration of intravenous fluids and, when appropriate, a vasopressor.

If not treated immediately, both convulsions and cardiovascular depression can result in hypoxia, acidosis, bradycardia, arrhythmias and/or cardiac arrest. If cardiac arrest should occur, standard cardiopulmonary resuscitative measures should be instituted.

For additional information about overdose treatment, call a poison control center ().


How should I store and handle Orabloc?

Store at 20° to 25°C (68 to 77°F);excursions permitted to 15° to 30° C (59° to 86°F) [See USP Controlled Room Temperature]. Protect from moisture. Dispense in tight, child-resistant container (USP).Clorazepate Dipotassium Tablets USP are available as tablets containing 3.75 mg, 7.5 mg or 15 mg of clorazepate dipotassium, USP.The 3.75 mg tablets are round flat beveled edge, pale violet colored slightly mottled tablet. One side is scored and engraved with "T" above the score and "45" below the score. Other side is plain.Bottles of 100 (NDC 51672-4042-1) Bottles of 500 (NDC 51672-4042-2) Bottles of 1,000 (NDC 51672-4042-3) The 7.5 mg tablets are round flat beveled edge, orange colored, slightly mottled tablet. One side is scored and engraved with "T" above the score and "46" below the score. Other side is plain.Bottles of 100 (NDC 51672-4043-1) Bottles of 500 (NDC 51672-4043-2) Bottles of 1,000 (NDC 51672-4043-3) The 15 mg tablets are round flat beveled edge, pale pink colored, slightly mottled tablet. One side is scored and engraved with "T" above the score and "47" below the score. Other side is plain.Bottles of 100 (NDC 51672-4044-1) Bottles of 500 (NDC 51672-4044-2) Bottles of 1,000 (NDC 51672-4044-3) Clorazepate Dipotassium Tablets USP are available as tablets containing 3.75 mg, 7.5 mg or 15 mg of clorazepate dipotassium, USP.The 3.75 mg tablets are round flat beveled edge, pale violet colored slightly mottled tablet. One side is scored and engraved with "T" above the score and "45" below the score. Other side is plain.Bottles of 100 (NDC 51672-4042-1) Bottles of 500 (NDC 51672-4042-2) Bottles of 1,000 (NDC 51672-4042-3) The 7.5 mg tablets are round flat beveled edge, orange colored, slightly mottled tablet. One side is scored and engraved with "T" above the score and "46" below the score. Other side is plain.Bottles of 100 (NDC 51672-4043-1) Bottles of 500 (NDC 51672-4043-2) Bottles of 1,000 (NDC 51672-4043-3) The 15 mg tablets are round flat beveled edge, pale pink colored, slightly mottled tablet. One side is scored and engraved with "T" above the score and "47" below the score. Other side is plain.Bottles of 100 (NDC 51672-4044-1) Bottles of 500 (NDC 51672-4044-2) Bottles of 1,000 (NDC 51672-4044-3) Clorazepate Dipotassium Tablets USP are available as tablets containing 3.75 mg, 7.5 mg or 15 mg of clorazepate dipotassium, USP.The 3.75 mg tablets are round flat beveled edge, pale violet colored slightly mottled tablet. One side is scored and engraved with "T" above the score and "45" below the score. Other side is plain.Bottles of 100 (NDC 51672-4042-1) Bottles of 500 (NDC 51672-4042-2) Bottles of 1,000 (NDC 51672-4042-3) The 7.5 mg tablets are round flat beveled edge, orange colored, slightly mottled tablet. One side is scored and engraved with "T" above the score and "46" below the score. Other side is plain.Bottles of 100 (NDC 51672-4043-1) Bottles of 500 (NDC 51672-4043-2) Bottles of 1,000 (NDC 51672-4043-3) The 15 mg tablets are round flat beveled edge, pale pink colored, slightly mottled tablet. One side is scored and engraved with "T" above the score and "47" below the score. Other side is plain.Bottles of 100 (NDC 51672-4044-1) Bottles of 500 (NDC 51672-4044-2) Bottles of 1,000 (NDC 51672-4044-3) Clorazepate Dipotassium Tablets USP are available as tablets containing 3.75 mg, 7.5 mg or 15 mg of clorazepate dipotassium, USP.The 3.75 mg tablets are round flat beveled edge, pale violet colored slightly mottled tablet. One side is scored and engraved with "T" above the score and "45" below the score. Other side is plain.Bottles of 100 (NDC 51672-4042-1) Bottles of 500 (NDC 51672-4042-2) Bottles of 1,000 (NDC 51672-4042-3) The 7.5 mg tablets are round flat beveled edge, orange colored, slightly mottled tablet. One side is scored and engraved with "T" above the score and "46" below the score. Other side is plain.Bottles of 100 (NDC 51672-4043-1) Bottles of 500 (NDC 51672-4043-2) Bottles of 1,000 (NDC 51672-4043-3) The 15 mg tablets are round flat beveled edge, pale pink colored, slightly mottled tablet. One side is scored and engraved with "T" above the score and "47" below the score. Other side is plain.Bottles of 100 (NDC 51672-4044-1) Bottles of 500 (NDC 51672-4044-2) Bottles of 1,000 (NDC 51672-4044-3) Clorazepate Dipotassium Tablets USP are available as tablets containing 3.75 mg, 7.5 mg or 15 mg of clorazepate dipotassium, USP.The 3.75 mg tablets are round flat beveled edge, pale violet colored slightly mottled tablet. One side is scored and engraved with "T" above the score and "45" below the score. Other side is plain.Bottles of 100 (NDC 51672-4042-1) Bottles of 500 (NDC 51672-4042-2) Bottles of 1,000 (NDC 51672-4042-3) The 7.5 mg tablets are round flat beveled edge, orange colored, slightly mottled tablet. One side is scored and engraved with "T" above the score and "46" below the score. Other side is plain.Bottles of 100 (NDC 51672-4043-1) Bottles of 500 (NDC 51672-4043-2) Bottles of 1,000 (NDC 51672-4043-3) The 15 mg tablets are round flat beveled edge, pale pink colored, slightly mottled tablet. One side is scored and engraved with "T" above the score and "47" below the score. Other side is plain.Bottles of 100 (NDC 51672-4044-1) Bottles of 500 (NDC 51672-4044-2) Bottles of 1,000 (NDC 51672-4044-3) Clorazepate Dipotassium Tablets USP are available as tablets containing 3.75 mg, 7.5 mg or 15 mg of clorazepate dipotassium, USP.The 3.75 mg tablets are round flat beveled edge, pale violet colored slightly mottled tablet. One side is scored and engraved with "T" above the score and "45" below the score. Other side is plain.Bottles of 100 (NDC 51672-4042-1) Bottles of 500 (NDC 51672-4042-2) Bottles of 1,000 (NDC 51672-4042-3) The 7.5 mg tablets are round flat beveled edge, orange colored, slightly mottled tablet. One side is scored and engraved with "T" above the score and "46" below the score. Other side is plain.Bottles of 100 (NDC 51672-4043-1) Bottles of 500 (NDC 51672-4043-2) Bottles of 1,000 (NDC 51672-4043-3) The 15 mg tablets are round flat beveled edge, pale pink colored, slightly mottled tablet. One side is scored and engraved with "T" above the score and "47" below the score. Other side is plain.Bottles of 100 (NDC 51672-4044-1) Bottles of 500 (NDC 51672-4044-2) Bottles of 1,000 (NDC 51672-4044-3) Clorazepate Dipotassium Tablets USP are available as tablets containing 3.75 mg, 7.5 mg or 15 mg of clorazepate dipotassium, USP.The 3.75 mg tablets are round flat beveled edge, pale violet colored slightly mottled tablet. One side is scored and engraved with "T" above the score and "45" below the score. Other side is plain.Bottles of 100 (NDC 51672-4042-1) Bottles of 500 (NDC 51672-4042-2) Bottles of 1,000 (NDC 51672-4042-3) The 7.5 mg tablets are round flat beveled edge, orange colored, slightly mottled tablet. One side is scored and engraved with "T" above the score and "46" below the score. Other side is plain.Bottles of 100 (NDC 51672-4043-1) Bottles of 500 (NDC 51672-4043-2) Bottles of 1,000 (NDC 51672-4043-3) The 15 mg tablets are round flat beveled edge, pale pink colored, slightly mottled tablet. One side is scored and engraved with "T" above the score and "47" below the score. Other side is plain.Bottles of 100 (NDC 51672-4044-1) Bottles of 500 (NDC 51672-4044-2) Bottles of 1,000 (NDC 51672-4044-3)


&times

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

Articaine HCl is an amide local anesthetic. Local anesthetics block the generation and conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse and by reducing the rate of rise of the action potential. In general, the progression of anesthesia is related to the diameter, myelination, and conduction velocity of the affected nerve fibers. Epinephrine is a vasoconstrictor added to articaine HCl to slow absorption into the general circulation and thus prolong maintenance of an active tissue concentration.

Non-Clinical Toxicology
Orabloc® is contraindicated in patients who are hypersensitive to products containing sulfites. Products containing sulfites may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. Sulfite sensitivity is seen more frequently in asthmatic than in non-asthmatic people

(The following interactions are from a published review and include reports concerning both oral and topical salicylate administration. The relationship of these interactions to the use of SALVAX is not known.)

The following alterations of laboratory tests have been reported during salicylate therapy:

Accidental intravascular injection of Orabloc® may be associated with convulsions, followed by central nervous system or cardiorespiratory depression and coma, progressing ultimately to respiratory arrest. Dental practitioners who employ local anesthetic agents including Orabloc® should be well versed in diagnosis and management of emergencies that may arise from their use. Resuscitative equipment, oxygen, and other resuscitative drugs should be available for immediate use. To avoid intravascular injection, aspiration should be performed before Orabloc® is injected. The needle must be repositioned until no return of blood can be elicited by aspiration. Note, however, that the absence of blood in the syringe does not guarantee that intravascular injection has been avoided.

Small doses of local anesthetics injected in dental blocks may produce adverse reactions similar to systemic toxicity seen with unintentional intravascular injections of larger doses. Confusion, convulsions, respiratory depression and/or respiratory arrest, and cardiovascular stimulation or depression have been reported. These reactions may be due to intra-arterial injection of the local anesthetic with retrograde flow to the cerebral circulation. Patients receiving these blocks should be observed constantly. Resuscitative equipment and personnel for treating adverse reactions should be immediately available. Dosage recommendations should not be exceeded .

Reactions to articaine are characteristic of those associated with other amide local anesthetics. Adverse reactions to this group of drugs may also result from excessive plasma levels (which may be due to overdosage, unintentional intravascular injection, or slow metabolic degradation), injection technique, volume of injection, or hypersensitivity or they may be idiosyncratic.

&times

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

&times

Review

Rate this treatment and share your opinion


Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

This medication has worked for me.




This medication has been easy for me to use.




Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
&times

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
&times

Tips

Tips

&times

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).